 |
 |
||||||||||
Volume
6, April 2011 |
 |
||||||||||
 |
MaxCyte’s proprietary Flow Electroporation technology leads the way in high performance, high throughput transfection enabling the widest array of cost and time effective drug discovery assays. MaxCyte technology lets you get ahead by transfecting any molecule of interest, into any cell, at any scale. The goal of the MaxCyte Minute is to provide researchers like you with key application and scientific advancements to help you stay ahead in the world of drug discovery. |
||||||||||
IN THIS ISSUE
Company News MaxCyte Expands its Global Sales and Scientific Support Staff |
MaxCyte Expands its Global Sales and Scientific Support Staff in Response to Increased Demand for its Scalable Transfection Systems
|
||||||||||
|
New Resources
- Application Note Vol.5 - MaxCyte Tutorial - SBS 2011 Poster - SBS 2011 Poster - Drug Discovery Poster Upcoming
Events
PEGS May 9-13, 2011 Boston, MA Screening Europe June 30-July 1, 2011 Hamburg, Germany Frequently Asked Questions
Do you use the same electroporation protocols for protein production?   |
MaxCyte recently expanded its sales and scientific support teams through the addition of a North American West Coast Sales Manager, Jon S. Gringrich, and a European Field Application Scientist, Dr. Peer Heine. Both individuals join MaxCyte with strong backgrounds in cell-based applications. MaxCyte is dedicated to the global support of both its current and prospective clients and foresees the need for continued expansion as the demand for the MaxCyte® STX™ Scalable Transfection System increases.
Jon Gingrich has held Business Development and Sales Management positions with GMP Contact Manufacturing Organizations for Biologicals, Cell Culture Development, Protein Expression and Proteomics for over fifteen years. Jon has worked in the Protein Expression field servicing bio-pharmaceutical and academic accounts, as the National Sales Manager for the Protein Expression and Proteomics portfolio with Sigma Aldrich. Jon has a BS in Chemistry from CSUC.
Dr. Peer Heine joins MaxCyte after several years at Lonza as a Scientific Product Specialist focused on Transfection. Peer studied Neurobiology in Mainz (Germany) and obtained his PhD at the Max-Planck-Institute for Brain Research in Frankfurt am Main (Germany) followed by a postdoctoral position at Duke University in North Carolina. |
||||||||||
MaxCyte flow electroporation is a high efficiency method for transfecting a variety of adherent and suspension
cell types enabling production of proteins, including antibodies, in the quantities needed for pre-clinical product
development. While stable cell lines have been the standard for protein production for over two decades, MaxCyte
electroporation has become a practical solution to the time, labor and cost challenges faced when relying exclusively
on stable cell lines. The MaxCyte STX Scalable Transfection System provides a rapid, scalable solution for production
of antibodies, recombinant proteins, virus-like particles (VLPs) and viral vectors.
MaxCyte Electroporation for Protein Production: • Fully scalable, able to transfect up to 1x1010 cells in <30 minutes • Specialized protocols optimized for protein production • High quality transfection of CHO and other commonly used cells • Decreased reliance on stable cell lines • Sustained protein production for >10 days >> Read more about ANTIBODY PRODUCTION in CHO Cells If you are interested in learning more about using the MaxCyte STX for protein or antibody production, please contact a MaxCyte scientist for more information or to arrange an on-site demonstration. Tel: +1-301-944-1700 Email: info@maxcyte.com |
|||||||||||
|
|||||||||||
 |
|||||||||||
The MaxCyte STX comes pre-loaded with electroporation (EP) protocols specific for individual cell types.
Standard MaxCyte protocols provide an optimal blend of loading efficiency and cell viability, which are
ideally suited for generating cells for use in cell-based assays. MaxCyte has developed additional EP
protocols for CHO and HEK cells that maximize DNA loading for high level protein expression.
Increased Cell Loading with Optimized Electroporation Parameters. CHO cells were electroporated (EP) with 0, 200 or 400 µg/mL pGFP in small scale format (OC-100 processing assemblies) using either MaxCyte's standard CHO protocol or a CHO-specific protocol optimized for protein expression. Cells were seeded in shake flasks at approximately 1x106 cells/mL and assayed by FACS approximately 20 hrs post electroporation. Data are expressed for % cell viability, % GFP+ cells and the mean fluorescence intensity (MFI).
Figure 1 illustrates the differences in cell viability and transgene expression following transfection of CHO cells using the general or protein expression EP protocol. The protein expression protocol allows the user to load CHO cells with greater quantities of pGFP DNA and in turn, leads to an increase in average GFP expression per cell when compared with the standard CHO protocol. Although the effects of DNA toxicity may be more pronounced with the protein expression protocols, users can easily determine an optimal DNA concentration for achieving high protein titers while minimizing loss of viability by transfecting cells with several different concentrations of their protein expression plasmid(s) via small scale, static electroporations in OC-100 or OC-400 processing assemblies. The optimal DNA concentration for small scale protein production can be used to achieve comparable titers at large scale by transfecting up to 1x1010 cells using flow electroporation. |
|||||||||||
|
||||
